Loading…
← CockpitCompetitor Analysis › 688192.SS Dizal Pharmaceutical Co Ltd. Class AOpen in the cockpit ↗

Dizal Pharmaceutical Co Ltd. Class A688192.SSCompetitor analysis, valuation and peers

China · CNY·Industrials›Miscellaneous Commercial Services

Chinese biotech developing targeted small-molecule oncology drugs, including EGFR-mutant lung-cancer therapies.

≈ A China-based clinical-stage oncology biotechMomentum leader 88
Mkt cap
$4.02B
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$65.5M
20-day average traded
Fwd P/E
7.8×
forward earnings
ROIC−WACC
n/a
WACC 6.2%
Hurdle
-107 pp
Req g minus delivered
Next earnings
168 days
5 May 2027
Close · CNYCN¥57.89
1D-2.4%
1W-9.7%
1M-5.7%
3M-5.4%
6M+8.6%
YTD+0.5%
1Y-8.6%
ATR %6.3%
52w lowhigh18.8% off high

What Dizal Pharmaceutical does

Chinese biotech developing targeted small-molecule oncology drugs, including EGFR-mutant lung-cancer therapies.

Has moved from research to selling: its lead EGFR exon20 lung-cancer drug, sunvozertinib, is approved in China, so income now begins with drug sales to hospitals, topped up by licensing payments and investor funding for the rest of the pipeline. It trades on Shanghai's STAR board for science and technology companies.

In one line: A China-based clinical-stage oncology biotech.

Products and services

  • EGFR exon20 inhibitor programs
  • Other oncology pipeline candidates

Customers

  • Oncologists/hospitals
  • Pharma licensing partners

Where it sits in the supply chain

  • Biopharma
  • Small-molecule drug discovery
  • Targeted oncology therapies

What could go right

  • Pipeline approvals and ex-China licensing deals

What could go wrong

  • Clinical trial and regulatory risk

Moat: narrow (IP / patents). Patent-protected, clinically differentiated targeted-oncology pipeline.

Headquarters: Shanghai, China · Employees: 1,009

Named competitors

Dizal Pharmaceutical at a glance

Size Dizal Pharmaceutical (688192.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $4.02B, the 600th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥57.89 on 18 Nov 2026.

Performance Over six months the shares gained 8.6%, against +13.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 720.1% over the last twelve months (peer median +6.4%); the operating margin is 69.0% (peer median 10.6%).

Valuation It trades at 7.8× forward earnings against a peer median of 15.0× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +96%, so the hurdle is -107 pp: the price already allows for a slowdown.

Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 114688192.SS 114
Six months, rebased to 100: Dizal Pharmaceutical against the median of its 20 peers (local-currency closes).

Dizal Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.98BCN¥801MCN¥359MCN¥90.9MCN¥0
Revenue growth—+123%+295%——
Gross profitCN¥4.94BCN¥691MCN¥273MCN¥15.0M-CN¥63.1M
EBITDAn/a-CN¥745M-CN¥897M-CN¥1.08B-CN¥730M
Net incomeCN¥3.45B-CN¥764M-CN¥846M-CN¥1.11B-CN¥736M
Free cash flowCN¥3.41B-CN¥759M-CN¥788M-CN¥1.00B-CN¥677M
Capital expenditureCN¥70.2MCN¥170MCN¥138MCN¥32.1MCN¥73.8M
Total debtCN¥1.29BCN¥1.24BCN¥1.16BCN¥410MCN¥85.3M

Quarterly statements and history in the cockpit →

Dizal Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-20%-10%0%+10%300012PWLSAILIFEGEO17972331TEPMTOLTTSLOOMISMMSAALBBCOSRPABM688318REYTNET300803IKS688192.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Dizal Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%0×50×100×300012PWLSAILIFEGEO17972331TEPLTTS688318300803688192.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dizal Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%300012GEO17972331TEPMTOLTTSLOOMISBCO300803IKS688192.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dizal Pharmaceutical is the large dot.

Dizal Pharmaceutical competitors and peer comparison

Head to head with its named competitors (688192.SS vs 688578.SS vs 3692.HK vs 300558.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Dizal Pharmaceutical 688192.SS$4.02B+9%+720%69%7.8×-11.0%
Shanghai Allist Pharmaceuticals 688578.SS$5.32B-14%+39%47%12.4×0.1%
Hansoh Pharma 3692.HK$25.3B-3%+25%38%25.8×7.9%
Betta Pharmaceuticals 300558.SZ$2.70B-15%+16%11%38.0×23.2%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
HUTCHMED (China) 0013.HK$2.38B+14%-9%-6%35.9×47.0%

How Dizal Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dizal Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688192.SSPeer medianRank in peer set
1-month return-5.7%-0.3%6th lowest of 21
6-month return+8.6%+13.9%9th lowest of 21
Distance from 52-week high-18.8%-12.7%6th lowest of 21
Revenue growth (TTM)+720.1%+6.4%highest of 21
Operating margin69.0%10.6%highest of 21
Forward P/E7.8×15.0×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)-11.0%2.6%least demanding of 18
Growth delivered (Del g)+95.9%+9.7%highest of 18
Hurdle (Req g minus delivered)-106.9 pp-8.1 ppleast demanding of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dizal Pharmaceutical 688192.SSChina$4.02B+9%+720%69%7.8×-11.0%+95.9%
Centre Testing International 300012.SZChina$4.00B+3%+15%16%22.2×14.4%+13.2%
PhysicsWallah PWL.NSIndia$3.99B+13%+35%1%118.1×n/an/a
SAI Life Sciences SAILIFE.NSIndia$4.07B+59%+16%22%87.2×n/an/a
GEO GEOUnited States$4.22B+37%+15%13%15.5×5.7%+2.3%
East Buy 1797.HKHong Kong$3.79B+21%+34%11%36.2×17.3%+54.3%
Alsok 2331.TJapan$4.36B+23%+7%9%13.5×-4.5%+4.9%
Teleperformance TEP.PAFrance$4.42B+5%-3%10%5.0×-10.2%+12.2%
MITIE MTO.LUnited Kingdom$3.48B+18%+11%3%14.1×14.3%+17.6%
L&T Technology Services LTTS.NSIndia$4.64B+15%+2%15%28.3×30.2%+15.1%
Loomis LOOMIS.STSweden$3.47B+15%+1%11%13.5×-8.7%+9.7%
MAXIMUS MMSUnited States$3.42B+9%-3%11%7.9×-8.2%+9.4%
Aalberts AALB.ASNetherlands$4.74B+1%0%10%14.6×13.1%+3.4%
Brink's BCOUnited States$4.80B+9%+7%10%12.4×1.2%+7.3%
Serco SRP.LUnited Kingdom$3.23B-7%+1%5%13.7×0.8%+4.9%
ABM Industries ABMUnited States$3.21B+38%+6%5%13.0×-1.1%+7.9%
Shenzhen Fortune Trend Technology 688318.SSChina$3.13B-28%-3%56%64.8×n/an/a
Reply REY.MIItaly$5.20B+23%+6%13%16.7×2.6%+14.4%
TriNet TNETUnited States$2.95B+51%-4%6%14.5×-3.7%+4.4%
Beijing Compass Technology Development 300803.SZChina$5.57B-39%+12%0%164.4×44.4%+25.3%
Inventurus Knowledge Solutions IKS.NSIndia$2.88B-2%+43%28%28.1×25.8%+45.8%

Questions

Who are Dizal Pharmaceutical's main competitors?
Named competitors: Allist Pharmaceuticals (688578.SS), Hansoh Pharmaceutical (3692.HK), Betta Pharmaceuticals (300558.SZ), AstraZeneca (AZN.L), Johnson & Johnson (JNJ), Hutchmed (0013.HK). The cockpit's measured peer set (industry) also includes Centre Testing International (300012.SZ), PhysicsWallah (PWL.NS), SAI Life Sciences (SAILIFE.NS), GEO (GEO), East Buy (1797.HK), Alsok (2331.T).
Is Dizal Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 7.8× against a peer median of 15.0×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +96%, so the hurdle is -107 pp: the price already allows for a slowdown.
How has Dizal Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +8.6% against +13.9% for the median peer; over one year -8.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.